Clinical trial NCT06283082: Oxalate Excretion Profile in Patients with a Heterozygous Mutation of the AGXT (alanine-glyoxylate Aminotransferase) Gene
Official title: Oxalate Excretion Profile in Patients with a Heterozygous Mutation of the AGXT (alanine-glyoxylate Aminotransferase) Gene - Influence of Hygienic and Dietary Conditions and Identification of Favouring Factors by Comparison of Asymptomatic and Symptomatic Patients (lithiasis or Oxalic Nephropathy)
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Hyperoxaluria (Disorder)
Keywords: AGXT heterozygous mutation
lithiasis
nutrition
nephropathy
Lead sponsor: Hospices Civils de Lyon
Sponsor class: OTHER
First posted: 2024-02-28
Enrollment: 25
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: Primary hyperoxaluria type I (PH1) is a rare genetic disorder responsible for severe lithiasis leading to progressive deterioration of renal function and end-stage renal failure. PH1 is linked to a deficiency in glyoxylate amino transferase (AGXT), which leads to increased endogenous oxalate synthesis and hyperoxaluria. In the urine, urinary oxalate precipitates with calcium, forming insoluble crystals, leading to lithiasis and the development of nephrocalcinosis.

Non-genetic etiologies of oxalic nephropathy are well known, in particular enteric causes (malabsorptions, bypass, calcium deficiencies, etc.) and sometimes linked to increased oxalate intake in the form of nutritional or vitamin supplements, reinforcing the hypothesis of probably underestimated favouring factors of hyperoxaluria.

Until now, heterozygous patients with a mutation in the AGXT gene were considered asymptomatic. However, there have been several cases of patients with heterozygous AGXT mutations presenting with lithiasis.

Consequently, the characteristics of symptomatic and asymptomatic heterozygous patients will be studied in order to define the elements that would explain the expression of the disease (particularities of the AGXT mutation, presence of another heterozygous mutation or favorable living conditions).

The hypothesis is that there is an increase in hepatic oxalate production in heterozygous patients, which explains why they remain asymptomatic under usual conditions, but could favor stone formation under favorable conditions such as severe calcium deficiency or malabsorption.


Eligibility criteria: Inclusion Criteria:

* Presenting an heterozygous mutation on AGXT
* Presenting symptoms (presence or history of stones, nephrocalcinosis) or not

Exclusion Criteria:

* Individuals unable to provide 24-hour urine samples.
* Individuals unable to free up a morning for day hospital appointments
* Individuals deprived of liberty by a judicial or administrative decision.
* Adults under a legal protection measure (guardianship, trusteeship).
* Individuals placed under judicial protection.
* Participants enrolled in another study with an ongoing exclusion period
* Pregnant women.
* Individuals not covered by social security

Primary outcomes:
measure: Urinary oxalate and glycolate excretion
timeFrame: At Day 0
Secondary outcomes:
measure: The prevalence of stones
timeFrame: At Day 0
measure: Lithiasis disease severity
timeFrame: At Day 0
measure: Lithiasis disease severity
timeFrame: At Day 0
measure: Lithiasis disease severity
timeFrame: At Day 0
measure: Lithiasis disease severity
timeFrame: At Day 0
measure: Predisposing conditions for lithiasis disease
timeFrame: At Day 0
measure: Predisposing conditions for lithiasis disease
timeFrame: At Day 0
Other outcomes:
Locations:
city: Lyon
country: France
facility: CLIMA, pavillon R, Hôpital Edouard Herriot
Study officials:
References: